Experience

Our Work

At Endpoint Outcomes, our work is focused on producing valid, reliable results for our clients.

THERAPEUTIC AREAS

We have experience across many therapeutic areas.

i

PUBLICATIONS

Published works highlighting our projects and research.

j

RESEARCH

Our Qualitative Research on Rating Scales.

THERAPEUTIC AREA EXPERIENCE

Cardiology - Vascular Disease
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Cardiomyopathy
Raynaud's Disease
Endocrinology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Obesity
Dermatology/Aesthetics
Disease/Condition/Syndrome  Services Provided    
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Acne
Atopic Dermatitis
Body Contouring
Body Sculpting
Facial Lines
Hyperhydrosis
Jowls
Lower Eyelid Steatoblepharon
Masseter Muscle Hypertrophy
Periorbital Aesthetics
Plaque Psoriasis
Platysma
Rosacea
Sebum Production
Skin Quality
Gastroenterology
Disease/Condition/Syndrome  Services Provided    
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Abdominal Pain
Bowel Prep
Celiac Disease
Chronic Constipation
Crohn's Disease
Eosinophilic Esophagitis
Functional Dysepsia
Gastroesophageal Reflux Disease
Gastroparesis
Irritable Bowel Syndrome
Short Bowel Syndrome
Genetic/Rare Diseases
Disease/Condition/Syndrome  Services Provided    
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Alagille Syndrome
Dravet Syndrome
Eosinophilic Esophagitis
Fabry Disease
Gastroparesis
Glycogen Storage Disorder Type 1a (GSD1a)
Hemophilia
Hereditary ATTR Amyloidosis (hATTR)
Hypoparathyroidism
Idiopathic Pulmonary Fibrosis
Impulsive Aggression
Kabuki Syndrome
Mastocytosis
Methylmalonic Acidemia
Ornithine Transcarbamylase (OTC)
Porphyria
Primary Biliary Cirrhosisn
Primary Hyperoxaluria (PH1)
Primary Hyperoxaulria
Propionic Acidemia
Pyruvate Kinase Deficiency
Raynaud's Disease
Sanfilippo Disorder
Short Bowel Syndrome
Sickle Cell Anemia
Tumor-induced Osteomalacia (TIO)
X-Linked Hypophosphatemia
Hematology
Disease/Condition/Syndrome  Services Provided    
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Hemophilia
Hypoparathyroidism
Pyruvate Kinase Deficiency
Sickle Cell Anemia
Hepatology
Disease/Condition/Syndrome  Services Provided    
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Primary Biliary Cirrhosis
Primary Hyperoxaluria
Nephrology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Kidney Disease
Primary Hyperoxaluria (PH1)
Neurology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Alzheimer's disease
Autism
Cataplexy/Narcolepsy
Cervical Dystonia
Chronic Lower Back Pain
Dravet Syndrome
Epilepsy
Fibromyalgia
Migraine
Multiple Sclerosis
Neuropathic Pain
Parkinson's Disease
Radicular pain
Spasticity
Tardive Dyskinesia
Tension Headache
Obstetrics/Gynecology (Women’s Health)
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Endometriosis
Leiomyomas
Uterine Fibroids
Vulvodynia
Oncology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Basel Cell Carcinoma
Breast Cancer
Glioma
Lung Cancer
Metastatic Solid Malignancy
Not Specific
Prostate Cancer
Thyroid Cancer
Ophthalmology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Diabetic Macular Edema
Dry Eye
Geographic Atrophy
Glaucoma
Presbyopia
Pediatrics
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Acne
Alagille Syndrome
Atopic Dermatits
Autism Spectrum Disorder
Cataplexy/Narcoplexy
Dravet Syndrome
Eosinophilic Esophagitis
Glycogen Storage Disorder Type 1a (GSD1a)
Hemophilia
Impulsive Aggression
Kabuki Syndrome
Methylmalonic Acidemia
Ornithine Transcarbamylase (OTC)
Primary Hyperoxaluria (PH1)
Propionic Acidemia
Pyruvate Kinase Deficiency
Sanfilippo Disorder
Psychiatry
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Binge Eating
Impulsive Aggression
Postpartum depression
Pulmonary/Respiratory Diseases
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Allergic Rhinitis
Asthma
Idiopathic Pulmonary Fibrosis
Mastocytosis
Rheumatology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Gouty Arthritis
Osteoarthritis
Rheumatology
Urology
Disease/Condition/SyndromeServices Provided      
Literature Review/Gap AnalysisDevelopmentValidationeCOAStrategyCommunicationOther
Interstitial cystitis
Overactive bladder
Premature Ejaculation
i

PUBLICATIONS

Journal Articles

Grace RF, Cohen J, Egan S, Wells T, Witherspoon B, Ryan A, Salek SS, Bodie S, Klaasen RJ. The Burden of Disease in Pyruvate Kinase Deficiency: Patients’ Perception of the Impact on Health-Related Quality of Life. European Journal of Haematology 2018; In press.

Hwang S, Van nooten F, Wells T, Ryan A, Crawford B, Evans C, English, M. Neuropathic pain: A patient-centred approach to measuring outcomes. Health Expectations 2018; 1-13.

Brenner DM, Dove LS, Andrae DA, Covington PS, Gutman C, Chey WD. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil. 2018; e13331.

Kelleher C, Chapple C, Johnson N, Payne C, Homma Y, Hakimi Z, Siddiqui E, Evans C, Egan S, Kopp Z. Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. Neurourology and Urodynamics 2017; 1-10.

Benmedjahed K, Wang G, Lambert J, Evans C, Hwang S, Black J, Johns MW.  Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported measures. Sleep Medicine 2017; 32:143-149.

Hudgens S, Evans C, Philips E, Hill M.  Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. Journal of Patient Reported Outcomes 2017;1:3.

Wang YG, Benmedjahed K, Lambert J, Evans C, Hwang S, Black J, Johns MW.  Assessing narcolepsy and cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. Nature and Science of Sleep 2017;9:201-211.

Kamath BM, Abetz-Webb L, Kennedy C, Hepburn B, Gauthier MJohnson N, Medendorp S, Dorenbaum A, Todorova L, Shneider BL. Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis.  The Patient – Patient-Centered Outcomes Research 2017;10.

Chey WD, Dove LS, Andrae DA, and Covington PS. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhea in two Phase 3 studies. Aliment Pharmacol Ther 2017;45:1319–1328.

Buono JL, Mathur K, Averitt AJ, and Andrae DA. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. Journal of Medical Economics 2017;20(4):353-362.

Buono JL, Mathur K, Averitt AJ, and Andrae DA.  Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. Journal of Managed Care & Specialty Pharmacy 2017;23(4):453-460.

Boeltzig-Brown H, Fleming A, Heyman M, Gauthier M, Cully J, Foley S. A Systematic Review of State Vocational Rehabilitation Agency-Based Literature. Rehabilitation Research, Policy, and Education 2017;31(4):352-371.

Chapple CR, Kelleher CJ, Evans CJ, Kopp Z, Siddiqui E, Johnson N, Mako M. A narrative review of patient-reported outcomes in overactive bladder: what is the way of the future? European Urology 2016; 70(5): 799-805.

Lembo A, Lacy BE, Zuckerman M, Schey R, Dove LS, Andrae DA et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea.  New England Journal of Medicine 2016;374(3):242-253.

Andrae DA, Covington PS, Patrick DL.  Item-Level Assessment of the Irritable Bowel Syndrome Quality of Life Questionnaire in Patients with Diarrheal Irritable Bowel Syndrome.  Clinical Therapeutics 2014;36(5):663-679.

Alexis A, Daniels S, Johnson N, Pompilus F, Burgess S, Harper J. Development of a new patient-reported outcome measure for facial acne: The Acne Symptom and Impact Scale (ASIS). Journal of Drugs in Dermatology 2014;13(3):333-340.

Brubaker L, Piault E, Tully S, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Khullar V, Kelleher CJ, Trocio J. Validation study of the Self-Assessment Goal Achievement (SAGA) questionnaire for lower urinary tract symptoms. International Journal of Clinical Practice 2013;67:342-350.

Stokes J, Evans C, Pompilous F, Shields A, Summers K. Development of a questionnaire to assess the impact of chronic low back pain for use in regulated clinical trials. The Patient: Patient-Centered Outcomes Research 2013;6(4):291-305.

Andrae DA, Patrick DL, Drossman D, Covington PS.  Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients.  Health and Quality of Life Outcomes 2013;11(1):208.

Covington PS, Davenport J, Andrae DA et al.  A phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.  Journal of Antimicrobial Chemotherapy 2013;68(11):2691-2693.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae DA et al.  Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study.  Gastroenterology 2013;145(2):329-338.

Johansen KL, Finklestein FO, Revecki DA, Evans C, Wan S, Gitlin M, Agodoa IL. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant 2012;27(6):2418-25.

Piault E, Doshi S, Brandt B, Angun C, Evans CJ, Bergqvist A, Torcio J. Linguistic validation of translation of the self-assessment goal achievement (saga) questionnaire from English. Health and Quality of Life Outcomes 2012;10:40.

Bombardier C, Evans CJ, Katz N, Mardekian J, Zlateva G, Simon L. Further qualification of a therapeutic responder index for patients with chronic low back pain. Journal of Rheumatology 2011;38:362-369.

Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J, Yeh Y, Kopp ZS, Kelleher CJ, Trocio J. Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol 2011;22:937-946.

Evans CJ, Chiou C-F, Fitzgerald KA, Evans WJ, Ferrell BR, Dale W, Fried LP, Gandra SR, Dennee-Sommers B, Patrick DL. Development of a new patient-reported outcome measure in sarcopeina. Journal of American Medical Directors Association 2011;12:226-233.

Ng-Mak DS, Fitzgerald K, Norquist J, Banderas B, Nelsen L, Evans C, Healy C, Ho T, Bigal M. Key concepts in migraine postdrome: a qualitative study to develop a post-migraine questionnaire. Headache 2011;51:105-117.

Covington PS, Davenport J, Andrae DA et al.  Randomized, Double-Blind, Phase II, Multicenter Study Evaluating the Safety/Tolerability and Efficacy of JNJ-Q2, a Novel Fluoroquinolone, Compared with Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infection.  Antimicrobial Agents and Chemotherapy 2011;55(12):5790-5797.

Boeltzig H, Klemm M, Fleming A, Cully J, Infante P, Lewandowski K, Gottshall C, Szenamici K, Luse MM, Mullins T. A selected look at the literature base on vocational rehabilitation and implications for future research. Report for the U.S. Department of Education, National Institute on Disability and Rehabilitation Research (U.S. DOE/NIDRR). 2010.

Boeltzig H, Kusminsky MN, Foley SM, Klemm M. Evaluation of the Parent-Professional Leadership in Education (APPLE) project: Final Report. Evaluation Report for the Federation for Children with Special Needs, Boston, MA; 2010.

Chakravarthy U, Wong T, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pliel A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31.

Johansen KL, Finkelstein F, Revicki D, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents.  American Journal of Kidney Diseases 2010;55(3):535-548.

Langdon SW, Dennee-Sommers B. Exploring the relationships between self-objectification, rationales, and use of water as a strategy for appetite suppression. Psychology, Health and Medicine 2010;15:17-25

Silverman S, Sadosky A, Evans C, Yeh Y, Alvir J, Zlateva G. Toward characterization and definition of fibromyalgia severity. BMC Musculoskeletal Disorders 2010;11:66.

Lasch KF, Evans CJ, Schatell D. A qualitative analysis of patient-reported symptoms of anemia. Nephrology Nursing Journal 2009;36(6):621-633.

Sadosky A, Dukes E, Evans C. Reliability of a 1-week recall period for the medical outcomes survey sleep scale (mos-s) in patients with fibromyalgia. Health and Quality of Life Outcomes 2009;7(12):1-20.

Evans C, Schien J, Nelson W, Crespi S, Gargiulo K, Horowicz-Mehler N, Panchal S. Improving patient and nurse outcomes: a comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using Delphi panels. Pain Management Nursing 2007;8(2):86-95.

Piault E, Evans C, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the overactive bladder satisfaction (OAB-S) questionnaire. Neurology and Urodynamics 2007;1-12.

Simon L, Evans C, Katz N, Bombardier C, West C, Robbins J, Copley-Merriman C, Markman J, Coombs J. Preliminary development of a responder index in chronic low back pain. Journal of Rheumatology 2007;34(6):1386-1391.

Evans CJ, Parthan A, Le K. Economic and humanistic burden of Fibromyalgia in the USA. Expert Opinion and Review in Pharmacoeconomics and Outcomes Research 2006; 6(3): 303-314.

Parthan A, Evans CJ, Le K. Chronic low back pain: epidemiology, economic burden and patient reported outcomes in the USA. Expert Opinion and Review in Pharmacoeconomics and Outcomes Research 2006;6(3):359-369.

Feldman S, Evans C, Russell M. Systematic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern managed care plan. Journal of Dermatological Treatment 2005;16(1):37-42.

Evans C. Health and work productivity assessment: state of the art or state of flux? Journal of Occupational and Environmental Health 2004;46:S3-S11.

Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Management Science 2004;7(1):43-49.

Evans C, Trudeau E, Mertzanis P, Marquis P, Pena B, Wong J, Mayne T. Development and validation of the pain treatment satisfaction scale (ptss): a patient satisfaction questionnaire for use in patients with acute and chronic pain. Pain 2004;112:254-266.

Evans C, Crawford B, Doyle J. Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research 2003;3(6):685-689.

Evans C, Mertzanis P, Abetz L. Measurement strategies for indirect costs in economic evaluations. Expert Review of Pharmacoeconomics and Outcomes Research 2003;3(6):703-716.

Evans C. Closing the credibility gap in patient reported outcomes. Expert Review of Pharmacoeconomics and Outcomes Research 2002;1-2.

Evans C, Crawford B. Proxy reports in pharmacoeconomic studies: applications and accuracy for resource utilization estimates. Journal of Research in Pharmaceutical Economics 2001;11(2):23-35.

Crawford B, Dukes E, Evans C. The value of providing quality of life information to managed care decision-makers. Drug Benefit Trends 2001;13(7):45-52.

Henke C, Genco R, Killoy W, Miller D, Evans C, Finkelman R. An economic evaluation of a chlorhexadine chip for treating chronic periodontitis: the CHIP (CHlorhexadine In Periodontitis) study. JADA 2001;132:1557-1569.

Evans C, Crawford B. Data collection methods in prospective economic evaluations: how accurate are the results? Value in Health 2000;3(4):277-286.

Evans C, Crawford B. Expert judgement: guidance and future use. PharmacoEconomics 2000;17(6):545-553.

Evans C, Crawford B. Direct medical costing for economic evaluations: methodologies and impact on study validity. Drug Information Journal 2000;34:173-184

Evans C, Dukes E, Crawford B. The role of pharmacoeconomic information in the managed care formulary decision making process. Journal of Managed Care Pharmacy 2000;6(2):112-121.

Evans C, Crawford B. Patient self-reports in pharmacoeconomic studies: their use and impact on study validity. PharmacoEconomics 1999;15(3):241-256.

Nuijten MJC, Hadjadjeba L, Evans C, van den Berg J. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. PharmacoEconomics 1998;14(4):433-445.

Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. PharmacoEconomics 1997;12(2 Pt1):121-29.

Presentations

Cala ML, Graham CA,  Lipton RB,  Lyn N, Dodick DW,  Burk C, Yu JS, Evans CJ,  Viswanathan HN. The Activity Impairment in Migraine – Diary (AIM-D): A novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment related to migraine in episodic and chronic migraine patients. 60th Annual Scientific Meeting of the American Headache Society; San Francisco, CA: June 28 – July 1, 2018.

Egan S, Gauthier M, Cala ML, Khurana L, Dallabrida SM, Evans C. Patient definitions of improvement: Most frequent reasons for defining disease improvement as reported by patients with diabetes, chronic obstructive pulmonary disease (COPD), depression or osteoarthritis (OA). International Society for Pharmacoeconomics and Outcomes Research 2018 Meeting; Baltimore, MD: May (19-23), 2018.

Gauthier M, Egan S, Ryan A, Khurana L, Dallabrida SM, Evans C. Do words matter? Patient perspectives on conceptually similar symptoms and impacts frequently utilized in patient-reported outcome measures. International Society for Pharmacoeconomics and Outcomes Research 2018 Meeting; Baltimore, MD: May (19-23), 2018.

Graney B, Johnson N, Evans C, Ryan A, et al. Living with Idiopathic Pulmonary Fibrosis (L-IPF): Developing a Patient-Reported Symptom and Impact Questionnaire to Assess Health-Related Quality of Life in IPF. American Thoracic Society Conference; Washington DC: 19-24 May 2017.

Tutuncu A, Egan S, Evans CJ, Cala ML, Ryan A, Khurana L, Dallabrida SM.  Proximal versus distal impacts of disease: Drivers of bothersomeness ratings in Patient-Reported Outcome (PRO) studies. International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting; Boston, MA: May (20-24), 2017.

Tutuncu A, Egan S, Evans CJ, Ryan A, Cala ML, Khurana L, Dallabrida SM.  What is being measured in Patient-Reported Outcome (PRO) measures?  Symptom questions may often reveal impact answers.  International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting; Boston, MA: May (20-24), 2017.

Evans CJ, Serrano D, Witherspoon B, Khurana L, Dallabrida SM.  Are patients’ responses to five point verbal descriptor scales and visual analogue scales replicate measures? An experimental manipulation.  International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting; Boston, MA: May (20-24), 2017.

Evans CJ, Serrano D, Witherspoon B, Khurana L, Dallabrida SM.  Pain assessment: A myriad of techniques to measure pain severity.  Does it matter which one is used?  International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting; Boston, MA: May (20-24), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Development and Validation of the Impact Assessment for Rosacea Facial Redness (IA-RFR). International Society for Pharmacoeconomics and Outcomes Research 22nd Annual Meeting; Boston, MA: May (20-24), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Patient-Rated Impact Assessment for Rosacea Facial Redness (IA-RFR): Results from REVEAL Pivotal Trials of Oxymetazoline Cream 1% vs Vehicle. International Society for Pharmacoeconomics and Outcomes Research 22nd Annual Meeting; Boston, MA: May (20-24), 2017.

Kelleher C, Chapple C, Johnson N, Payne C, Homma Y, Hakimi Z, Siddiqui E, Kopp Z, Evans C. Development of an overactive bladder assessment tool: A potential alternative to the bladder diary. 32nd Annual EAU Congress; London: March (24-28), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Development and validation of the Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR). The American Academy of Dermatology Annual Meeting; Orlando, FL: March (3-7), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Development and validation of the Symptom Assessment for Rosacea Facial Redness (SA-RFR). The American Academy of Dermatology Annual Meeting; Orlando, FL: March (3-7), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Patient-rated Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR): Results of two phase 3 pivotal trials of oxymetazoline cream 1% vs vehicle. The American Academy of Dermatology Annual Meeting; Orlando, FL: March (3-7), 2017.

Ferrusi I, Ahluwalia G, Andrae DA. Patient-rated Symptom Assessment for Rosacea Facial Redness (SA-RFR): Results of two phase 3 pivotal trials of oxymetazoline cream 1% vs vehicle. The American Academy of Dermatology Annual Meeting; Orlando, FL: March (3-7), 2017.

Serrano D, Gauthier M, Harrington M, Acevedo L. Psychometric validation of the Itch Reported Outcome (ItchRO™) Observer assessment in pediatric patients with Alagille syndrome or progressive familial intrahepatic cholestasis. 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016; Boston, MA: November (11-15), 2016.

Bjorner JB, Rendas-Baum R, Carson RT, Boer R, Tucker C, Andrae DA, Brazier, J. Mapping the Irritable Bowel Syndrome Quality of Life measure to the EuroQoL five dimensions questionnaire in patients with irritable bowel syndrome with diarrhoea. International Society for Outcomes Research 19th Annual European Congress; Vienna, Austria: October 29 – November 2, 2016.

Curry C, Gauthier M, Egan S, Ryan A, Graham C, Witherspoon B, Evans C, DeBusk K. Development of Novel Clinical Outcome Assessments (COAs) for Children and Caregivers to Assess Atopic Dermatitis Signs and Symptoms. International Society for Quality of Life Research 23nd Annual Conference; Copenhagen, Denmark: October 20, 2016.

Chey WD, Andrae DA, Dove LS, Covington PS. 1-month Treatment with Eluxadoline for IBS-D Predicts a Sustained Response: Continuation Analysis of Response in Two Phase 3 Studies. United European Gastroenterology Week; Vienna, Austria: October (15-19), 2016.

Harris LA, Lucak S, Chang L, Gutman C, Andrae DA, Dove LS, Covington PS. Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. American College of Gastroenterology Annual Scientific Meeting & Postgraduate Course; Las Vegas, NV: October (14-19), 2016.

Curry C, Gauthier M, Egan S, Ryan A, Graham C, Witherspoon B, Evans C, DeBusk K. A Comparison of Atopic Dermatitis Signs and Symptoms by Age and Reporter. 25th European Academy of Dermatology and Venereology Annual Congress; Vienna, Austria: September 28-October 2, 2016.

Chapple C, Kelleher CJ, Evans C, Kopp Z, Johnson N, Hakimi Z, Siddiqui E. Comprehensive Bladder Assessment Tool: Instrument Development. 46th Annual International Incontinence Society Conference; Tokyo, Japan: September (13-15), 2016.

Lembo A, Dove LS, Andrae DA, Davenport JM, Turner L, Covington PS. Effects of Eluxadoline on Abdominal Pain in Patients with Irritable Bowel Syndrome with Diarrhea: Results of Two Phase 3 Clinical Trials. PAIN week; Las Vegas, NV: September (6-10), 2016.

Buono JL, Mathur K, Averitt A, Andrae DA. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analyses of a US Commercially Insured Population. American Association of Nurse Practitioners National Conference; San Antonio, TX: June (21-26), 2016.

Chey WD, Andrae DA, Dove LS, Covington PS. A 1-month Trial for IBS-D Predicts a Durable Response: Continuation Analysis of Response in Two Phase 3 Studies. Digestive Diseases Week; San Diego, CA: May (21-24), 2016.

Andrae, DA. Supporting Drug Lifecycle with Data Analysis. Statistics in Action. University of Texas Department of Statistics and Data Sciences; Austin, TX: 2016.

Andrae, DA. Data Analysis as Part of Clinical Drug Development. Statistics in Action. University of Texas Department of Statistics and Data Sciences; Austin, TX: 2015.

Peterson J, Gauthier M, Piault E, DeBusk K, Buzaglo J, Eng-Wong J, Glazer J, Green M, Johnson J, Spears P, Evans C. Importance of the patient voice in drug development: Early-stage breast cancer and measurement gaps concerning the treatment experience. San Antonio Breast Cancer Symposium: December 8-12, 2015.

Cala M, Witherspoon B, Evans C, Dallabrida S. Where is Your Abdomen? Patient-Reported Abdomen Locations and Implications for Patient-Reported Outcome Assessments. International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress; Milan, Italy: November (7-11), 2015.

Burgess, SM, Gauthier M, Cala ML. Comparison of patient-reported outcomes requirements in medical guidelines for pain, migraine, rheumatoid arthritis, and systemic lupus erythematosus: Europe vs United States. International Society for Pharmacoeconomics and Outcomes Research 18th Annual European Congress; Milan, Italy: November (7-11), 2015.

Buono JL, Andrae DA, Covington PS. Effect of Eluxadoline on Health-Related Quality of Life in Adults with Irritable Bowel Syndrome with Diarrhea: Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials. United European Gastroenterology Week; Barcelona, Spain: October (24-28), 2015.

Chey WD, Dove LS, Andrae DA, et al. Eluxadoline Demonstrates Sustained Efficacy for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome in Phase 3 Clinical Trials. United European Gastroenterology Week; Barcelona, Spain: October (24-28), 2015.

Lacy B, Dove LS, Andrae DA, et al. Robustness of Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Across Numerous Results from Phase 3 Composite Endpoint Assessments in Phase 3 Clinical Trials of Efficacy and Safety. United European Gastroenterology Week; Barcelona, Spain: October (24-25), 2015.

Lembo A, Dove LS, Andrae DA, et al. Eluxadoline’s Effect on the Pain Component of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Phase 3 Clinical Trials. United European Gastroenterology Week; Barcelona, Spain: October (24-28), 2015.

Zuckerman M, Dove LS, Andrae DA, et al. Robustness of Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Comparing a Novel Composite Endpoint to Classical Adequate Relief and to a recent Global Symptom Assessment Endpoint. United European Gastroenterology Week; Barcelona, Spain: October (24-28), 2015.

Curry C, Gauthier M, Cala ML, Egan S, Witherspoon B, Evans C, Fitzgerald K. Development of Novel Patient-Reported Outcomes (PRO) Instruments to Assess Atopic Dermatitis Signs, Symptoms and Impacts. International Society for Quality of Life Research 22nd Annual Conference; Vancouver, BC: October 24, 2015.

Buono JL, Mathur K, Averitt A, Andrae DA. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analyses of a US Commercially Insured Population. American College of Gastroenterology Annual Scientific Meeting; Honolulu, HI: October (16-21), 2015.

Chapple C, Kelleher CJ, Evans C, Kopp Z, Johnson N, Hakimi Z, Siddiqui E. Assessing outcomes in OAB: What is the way of the future? 45th Annual International Incontinence Society Conference; Montreal, CA: October (6-9), 2015.

Andrae DA, Buono JL, Covington PS. Effect of Eluxadoline on Health-Related Quality of Life in Adults with Irritable Bowel Syndrome with Diarrhea: Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Chey WD, Dove LS, Andrae DA, et al. Eluxadoline Demonstrates Sustained Efficacy for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome in Phase 3 Clinical Trials. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Covington PS, Dove LS, Andrae DA. A Retrospective Assessment of Area under the Pain Curve in Quantifying Daily Pain Assessments in IBS-D. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Lacy B, Dove LS, Andrae DA, et al. Robustness of Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Across Numerous Results from Phase 3 Composite Endpoint Assessments in Phase 3 Clinical Trials of Efficacy and Safety. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Lembo A, Dove LS, Andrae DA, et al. Eluxadoline’s Effect on the Pain Component of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Phase 3 Clinical Trials. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Zuckerman M, Dove LS, Andrae DA, et al. Robustness of Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Comparing a Novel Composite Endpoint to Classical Adequate Relief and to a Recent Global Symptom Assessment Endpoint. Digestive Disease Week; Washington, DC: May (16-19), 2015.

Andrae, DA. Data Analysis as Part of Clinical Drug Development. Statistics in Action. University of Texas Department of Statistics and Data Sciences; Austin, TX: 2015.

Witherspoon B, Misra Burgess S, Miskala P. Developments and communication since the issuance of FDA’s Guidance to Industry on Patient-Reported Outcomes: then and now. International Society for Pharmacoeconomics and Outcomes Research 20th Annual International Meeting; Philadelphia, PA: May (16-20), 2015.

Abetz-Webb L, Kennedy C, Hepburn B, Gauthier M, Johnson N, Menendorp S, Dorenbaum A, Shneider B, Kamath B. The Burden of pruritus on patients with Alagille syndrome: results from a qualitative study with pediatric patients and their caregivers. 65th Annual Meeting of the American Association for the Study of Liver Diseases; The Liver Meeting: November, 2014.

Arbuckle R, Witherspoon B, Carson R. Treatment expectations and drivers of treatment satisfaction among chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) patients. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA: October (17-22), 2014.

Lembo A, Andrae D, Dove LS, Covington PS. Urgency as a Measure of Treatment Effect Due to Eluxadoline. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA: October (17-22), 2014.

Lacy B, Almenoff J, Andrae D, et al. Eluxadoline Demonstrates Efficacy in Loperamide Treatment Failures. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA: October (17-22), 2014.

Lembo A, Dove, LS, Andrae D, et al. Eluxadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: Results of 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Trials of Efficacy and Safety. Digestive Disease Week; Chicago, IL: May (3-6), 2014.

Andrae DA. Psychometrics in IBS Drug Development. Statistics in Action. University of Texas Department of Statistics and Data Sciences; Austin, TX: 2014.

Holloway L, Arbuckle R, Carson R, Dennee-Sommers B, Abetz, L. Agreement between child and parent symptom diary responses in chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C): Implications for the measurement of symptoms in young children. International Society for Pharmacoeconomics and Outcomes Research European Congress: Dublin, Ireland: November (2-6), 2013.

Arbuckle R, Holloway L, Carson R, Dennee-Sommers B, Abetz L. The value of pilot testing PRO symptom diaries prior to conducting cognitive debriefing interviews in children/adolescents: qualitative and quantitative insights. International Society for Pharmacoeconomics and Outcomes Research European Congress; Dublin, Ireland: November (2-6),2013.

Hwang S, Evans C, Rothman M, Hao Y. Health-related quality of life in metastatic castration-resistant prostate cancer. International Society for Pharmacoeconomics and Outcomes Research; New Orleans, LA: May (18-22), 2013.

Hao Y, Evans C. A critical review of EMA labeling claims in oncology: 2006-2012. International Society for Pharmacoeconomics and Outcomes Research; New Orleans, LA: May (18-22), 2013.

Andrae DA. Enhancing traditional clinical trial outcomes with psychometrics. Statistics in Action. University of Texas Division of Statistics and Scientific Computation; Austin, TX: 2013.

Andrae DA. Psychometrics in Clinical Drug Development. Statistics in Action. University of Texas Division of Statistics and Scientific Computation; Austin, TX: 2013.

Covington P, Andrae D, Randall C, et al. MuDelta Treatment Improves Bowel Movement Frequency and Urgency Episodes in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Results of a Phase 2 Clinical Trial. Digestive Disease Week; San Diego, CA: May (19-22), 2012.

Andrae, DA. Extending the Quantitative Evaluation of PRO Items beyond Classical Test Theory Methods. CBI’s 9th Forum on Patient Reported Outcomes; Philadelphia, PA: May (7-8), 2012.

Andrae DA. Statistical Sciences in Clinical Drug Development. Statistics in Action. University of Texas Division of Statistics and Scientific Computation; Austin, TX: 2012.

Andrae DA. Joint Modeling of Multivariate Outcomes of Different Types.  Austin Chapter of the American Statistical Association; Austin, TX: 2012.

Klemm M, Haines K. Findings from the Rehabilitation Research and Training Center on Vocational Rehabilitation. TASH Annual Conference; Atlanta, GA: December, 2011.

Klemm M, Haines K. Strategies to minimize the effects of reporting errors through strategic web-survey design in program evaluation. American Evaluation Association Annual Conference; Anaheim, CA: November, 2011.

Klemm M. Evaluating the effectiveness of a professional development Program on student outcomes based on educator perceptions. American Evaluation Association Annual Conference; Anaheim, CA: November, 2011.

Randall C, Covington P, McIntyre G, Almenoff J, Davenport JM, Andrae D, Dove LS. MuDelta Treatment for Diarrhea-predominant Irritable Bowel Syndrome. American College of Gastroenterology Annual Scientific Meeting; Washington, DC: October 28 – November 2, 2011.

Yaworsky A, Daniels S, Fitzgerald K, Galipeau N, Kornstein A, Evans C, Misra-Burgess S. Content assessment of the facial line outcomes (FLO-11) questionnaire. International Society for Quality of Life Research 18th Annual Conference; Denver, CO: October (26-29), 2011.

Dennee-Sommers B, Galipeau N, Fitzgerald K, Evans C, Daniels S, Burgess SM. Gap analysis of patient-reported outcome measures for alopecia. International Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting; Baltimore, MD: May (21-25), 2011.

Carson RT, Lewis B, Shiff S, Johnston JM, Dennee-Sommers B, Lasch K, Hwang S, Marquis M. IBS-C patient symptom reports: Analysis of exploratory open-ended questions. International Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting; Baltimore, MD: May (21-25), 2011.

Lambe J, Acquadro C, Conway K, Ng-Mak D, Norquist J, Healy C, Nelsen L, Fitzgerald K, Evans C, Banderas B. Translatability assessment of the post-migraine questionnaire. International Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting; Baltimore, MD: May (21-25), 2011.

Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, Agodoa IL. Systematic Review of the Impact of Erythropoiesis Stimulating Agents on Fatigue in Dialysis Patients. National Kidney Foundation 2011 Spring Clinical Meetings; Las Vegas, NV: April (26-30), 2011.

Evans C, Fitzgerald K, Varon S, Bloudek L, Banderas B, Blumenfeld A. Development of a new patient-reported outcome measure in chronic migraine. American Academy of Neurology 63rd Annual Meeting; Honolulu, HI, USA: April (9-16), 2011.

Vo P, Chambers J, Evans C, Nothaft W, Duan R, Marx S. Systematic literature review on the burden of illness in osteoarthritis. Osteoarthritis Research Society International Meeting; Brussels, Belgium: September (23-26), 2010.

Andrae DA, Davenport JM. Comparing the Performance of Composite Endpoints and Responder Definitions with a Unified Modeling Framework for Multiple Endpoints within Clinical Trials. Joint Statistical Meetings; Vancouver, BC: July 31 – August 5, 2010.

Ng-Mak DS, Fitzgerald K, Norquist J, Evans C, Nelson LM, Banderas B, Healy C, Ho T, Bigal M. Post-Migraine Questionnaire (PMQ): a new instrument to assess symptoms and symptom impacts from patients’ perspective. 52nd Annual Scientific Meeting of the American Headache Society; Los Angeles, CA: June (24-27), 2010.

Vo P, Chambers J, Evans C, Dennee-Sommers B, Wolfram N, Marx S. Systematic literature review on the burden of illness in fibromyalgia. American Pain Society; Baltimore, MD: May (6-8), 2010.

Vo P, Chambers J, Evans C, Dennee-Sommers B, Wolfram N, Marx S. Systematic literature review on the burden of illness in painful diabetic peripheral neuropathy. American Pain Society; Baltimore, MD: May (6-8), 2010.

Silverman S, Sadosky A, Evans C, Yeh Y, Alvir J, Zlateva G. Assessing fibromyalgia severity. World Institute of Pain 2009, 5th World Congress; New York, NY: March (13-16), 2009.

Andrae DA. Protocol Design and Statistical Evaluation of Clinical Studies.  Integrated Product Development. 2009.

Jansen JP, Evans CJ, Guyot M, Masaquel C, Mayne TJ.  The impact of epoetin alfa on symptoms of anemia: a Bayesian meta-analysis of clinical trials. American Society of Nephrology; San Francisco, CA: October 31- November 5, 2007.

Brubaker L, Kopp Z, Piault E, Trocio J, Evans C, Fitzgerald K, Wong A. Development of a self-assessment goal achievement (SAGA) questionnaire in urinary disorders. 37th Annual Meeting of the International Continence Society; Rotterdam, the Netherlands: August (20-24), 2007.

Merkle E, Evans C, Feldman R. Patient satisfaction with a single pill treatment of hypertension and dyslipidemia. 8th Scientific forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference; Washington, D.C., MD: May (9-11), 2007.

Slavin R, Andrae DA. Qualitative Study of Cardinal Symptoms in Chronic Sinusitis. American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting; Washington, DC: 2007.

Nelson WW, Schein JR, Gargiulo K, Evans CJ.  Nursing times associated with intravenous patient-controlled analgesia (IV PCA) and fentanyl iontophoretic transdermal system (ITS): a comparison of estimates from 2 Delphi panels. 60th Annual Post Graduate Assembly in Anesthesiology; New York, NY, USA: December (8-12), 2006.

Kopp Z, Abrams P, Piault E, Evans C, Espindle D, Atkinson M, Brubaker L, Jumadilova Z. Patient satisfaction in studies of overactive bladder: A generic questionnaire versus a disease specific questionnaire. International Continence Society International Meeting; Christchurch, New Zealand: November 27 – December 1, 2006.

Jansen J, Evans C. The value and acceptability of a Bayesian framework for drug reimbursement and market access decision making. International Society for Pharmacoeconomics and Outcomes Research 11th Annual Meeting; Philadelphia, PA, USA: May (20-24), 2006.

Evans C, Piault E, Espindle D, Kopp Z, Brubaker L, Abrams P. Generic vs disease specific satisfaction measures: selecting a satisfaction measure for overactive bladder studies. Philadelphia, PA, USA; International Society for Pharmacoeconomics and Outcomes Research 11th Annual Meeting: May (20-24), 2006.

Coombs J, Evans C. Special interest group presentation on a responder index in low back pain. OMERACT; Malta: May (10-14), 2006.

Evans C, Katz N, Simon L, Bombadier C, West C, Robbins J, Copley-Merriman C, Coombs J. Development and preliminary validation of a responder index for patients with chronic low back pain. American Pain Society; San Antonio, TX, USA: May (3-6), 2006.

Piault E, Evans C, Marcucci G, Kopp Z, Brubaker L, Abrams P. Patient satisfaction: psychometric validation of the OAB-S, an overactive bladder treatment satisfaction questionnaire. International Society for Pharmacoeconomics and Outcomes Research 8th Annual European Congress; Firenze, Italy: November (6-8), 2005.

Evans C, Horowicz-Mehler N, Crawford B, Mertzanis P, Pena B, Mayne T. Satisfaction with pain medication and intention to comply with treatment: a structural equation model in rheumatoid arthritis. International Society for Pharmacoeconomics and Outcomes Research 10th Annual International Meeting; Washington, D.C, MD, USA: May (15-18), 2005.

Horowicz-Mehler N, Evans CJ, Abetz L, Copley-Merriman K. The content validity of clinician derived patient reported outcome measures: the Roland Morris Disability Questionnaire. International Society for Pharmacoeconomics and Outcomes Research 10th Annual International Meeting; Washington, D.C. MD, USA: May (15-18), 2005.

Evans C, Crawford B, Mesrobian X, Tavakoli M. Estimating the indirect costs of medical interventions: limitations of current strategies and the development of an integrated approach. 5th International Conference on Strategic Issues in Health Care Management; St. Andrews, Scotland: September (2-4), 2004.

Crawford B, Evans C, Tavakoli M. Do patients really care about others? An exploration of the impact of utility scores. 5th International Conference on Strategic Issues in Health Care Management; St. Andrews, Scotland: September (2-4), 2004.

Crawford B, Evans C, Tavakoli M. Understanding utility: do patients understand what we are asking them? 5th International Conference on Strategic Issues in Health Care Management; St. Andrews, Scotland: September (2-4), 2004.

Evans C. The search for the holy grail: establishing a valid methodology for measuring work productivity. International Society for Pharmacoeconomics and Outcomes Research Sixth Annual European Congress; Barcelona, Spain: November (9-11), 2003.

Feldman S, Evans C, Russell M. Treatment of psoriasis with conventional systemic agents is associated with high medical costs and frequent treatment failure. International Society for Pharmacoeconomics and Outcomes Research Sixth Annual European Congress; Barcelona, Spain: November (9-11), 2003.

Van Loon J, Crawford B, Monteban H, Evans C. How health care can benefit from changing the mindset: from cost and effectiveness to cost effectiveness. International Society for Pharmacoeconomics and Outcomes Research Sixth Annual European Congress; Barcelona, Spain: November (9-11), 2003.

Roberts H, Evans C, Sagrolikar A, Poulios N, Gomperts E. Development of an economic and outcomes model of hemophilia treatment in Latin America and South-East Asia. XIX Congress of the International Society of Thrombosis and Haemostasis; Birmingham, UK; July (12-18), 2003.

Evans C. Rationing in health care: can education make priority setting more efficient. 4th iHEA World Congress; San Francisco, CA, USA; June (15-18), 2003.

Crawford B, Evans C. Resource utilization estimates in economic evaluations: a comparison of economic data from a clinical trial to a cross-sectional database. 4th iHEA World Congress; San Francisco, CA, USA; June (15-18), 2003.

Evans C, Roberts HR, Sagrolikar A, Gomperts E. Hemophilia economic model of outcomes: Philippines case study. International Society for Pharmacoeconomics and Outcomes Research 8th Annual International Meeting; Crystal City, VA, USA: May (18-21), 2003.

Crawford B, Baron-Papillon F, Evans C, Horowitz-Mehler N. Economic and outcomes research in the real world: evaluation of its relevance. International Society for Pharmacoeconomics and Outcomes Research 8th Annual International Meeting; Crystal City, VA, USA: May (18-21), 2003.

Evans C. Hemophilia treatment in developing countries. World Federation of Hemophilia. 44th Annual Meeting of the American Society of Hematology; Philadelphia, PA, USA: December (6-10), 2002.

Crawford B, Gray C, Evans C, Piercy J, Arnould B. How to optimize communication of your results: achieving high impact communications. International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress; Rotterdam, the Netherlands: November (3-5), 2002.

Evans C. Criteria for reimbursement decisions. International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress: Rotterdam, the Netherlands: November (3-5), 2002.

Roberts H, Evans C, Gomperts E, Poulios N, Sagrolikar A. Development of an economic and outcomes model of hemophilia treatment in Latin America and South East Asia. International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress; Rotterdam, the Netherlands: November (3-5), 2002.

Evans C. Health economic education in allocation decisions: a pre-test post-test study. International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress; Rotterdam, the Netherlands: November (3-5), 2002.

Evans C, Mesrobian X, Crawford B. Benchmarks in economic evaluations: theoretical and practical shortcomings. Fourth Annual Workshop on Pharmaceutical Outcomes Research; Newport RI, USA: October (16-18), 2002.

Piercy J, Mesrobian X, Viala M, Evans C. Management of psoriasis in the UK primary care setting. 11th Congress of the European Academy of Dermatology and Venereology; Prague, Czech Republic: October (2-6), 2002.

Piercy J, Mesrobian X, Evans C, James P, Barker J. The burden of chronic plaque psoriasis (CPP) in the UK hospital sector. 11th Congress of the European Academy of Dermatology and Venereology; Prague, Czech Republic: October (2-6), 2002.

Piercy J, Mesrobian X, Evans C. Estimating the cost of moderate to severe chronic plaque psoriasis in the UK11th Congress of the European Academy of Dermatology and Venereology; Prague, Czech Republic: October (2-6), 2002.

Feldman S, Evans C. Systemic psoriasis treatment is costly and associated with a high likelihood of treatment failure. Academy 2000 Summer Meeting of the American Academy of Dermatology; New York, NY, USA: July 31-August 4, 2002.

Horowicz-Mehler N, Evans C, Crawford B, Mertzanis P, Pena B, Wong J, Mayne T. Structural equation modeling in a trial of rheumatoid arthritis patients: indicators of satisfaction with pain medication and intention to comply with treatment. Annual European Congress of Rheumatology; Stockholm, Sweden: June (12-15), 2002.

Evans C, Crawford B. The application of expert opinion in pharmacoeconomic studies. International Society for Pharmacoeconomics and Outcomes Research; Crystal City, VA: May (19-22), 2002.

Roberts H, Evans C. HEMO: Health Economic Model of Outcomes. XXV International Congress of the World Federation of Hemophilia; Seville, Spain: May (19-24), 2002.

Roberts H, Evans C, Gomperts E. Development of an economic and outcomes model of hemophilia treatment in Latin America and South East Asia. XXV International Congress of the World Federation of Hemophilia; Seville, Spain: May (19-2), 2002, and 29th World Congress of the International Society of Hematology; Seoul, Korea: August (24-28), 2002.

Trudeau E, Seignobos E, Evans C, Mertzanis P. Factors that influence patient satisfaction in colorectal cancer patients. American Society of Clinical Oncology (ASCO). 2002 Proceedings; Orlando, FL, USA: May (19-21), 2002.

Evans C, Crawford B, Mertzanis P, Tavakoli M. Interpreting endpoints in economic evaluations: analytic foundation and misleading conclusions. 5th International Conference in Strategic Issues in Health Care Management; St. Andrews, Scotland, UK: April (11-13), 2002.

Crawford B, Evans C, Tavakoli M. Theoretical models for utility: which model is better? 5th International Conference in Strategic Issues in Health Care Management; St. Andrews, Scotland, UK: April (11-13), 2002.

Feldman S, Piercy J, Vigliani G, Evans C. Development of an international model to measure the cost of care and cost effectiveness of treatments for psoriasis. 60th Annual Meeting of the American Academy of Dermatology; New Orleans, LA: February (22-27), 2002.

Crawford B, Evans C, Turner A, Karavali M. Disability, resource utilization, and work absences associated with osteoarthritis (OA) and rheumatoid arthritis (RA): an international database analysis.  International Society for Pharmacoeconomics and Outcomes Research; Cannes, France: November (11-13), 2001.

Marquis P, Evans C. Quality factors for health related quality of life assessment in clinical trials. 7th Annual National Health Outcomes Conference; Canberra, Australia: June (27-28), 2001.

Evans C, Crawford B, Miles A. Measurement strategies for productivity losses and work absences. International Society for Pharmacoeconomics and Outcomes Research: Antwerp, Belgium: November (5-7), 2000.

Baron F, Marquis P, Evans C, Crawford B. International comparison of pharmacoeconomic guidelines: consensus, divergence and practical implications. International Society for Pharmacoeconomics and Outcomes Research; Antwerp, Belgium: November (5-7), 2000. Value in Health 2000; 3 (5): 370.

Evans C, Crawford B, Hayes J, Cavallo F. Communication strategies for health outcomes studies. International Society for Pharmacoeconomics and Outcomes Research; Arlington, VA, USA: May (20-24), 2000.

Evans C, Crawford B, Dukes E. Technology assessment in the US: what do payers understand and what information do they want? ISPOR; Arlington, VA, USA: May (20-24), 2000.

Evans C, Kennedy L, Crawford B. The use of databases in health economics and outcomes research: an international perspective. 4th International Conference on Strategic Issues in Health Care Management; St Andrews, Scotland: March 30 – April 1, 2000.

Evans C, Kennedy L, Crawford B, Malek M. From guidelines to good practice: improving the quality of economic evaluations. 4th International Conference on Strategic Issues in Health Care Management; St Andrews, Scotland: March 30 – April 1, 2000.

Rovira J, Antonanzas F, Girod I, Arnould B, Crawford B, Evans C. The comparability and transferability of direct medical costs in international pharmacoeconomic studies. International Society for Pharmacoeconomics and Outcomes Research Second Annual European Conference; Edinburgh, Scotland: November 12, 1999.

Trudeau-Vanhems E, Marquis P, Evans C. Measurement of patient satisfaction with medical treatment. International Society for Pharmacoeconomics and Outcomes Research; Edinburgh, Scotland: November 12, 1999.

Evans C, Saal G, Crawford B. Structured decision making in pharmacoeconomic studies: a comparison and critique. International Society for Pharmacoeconomics and Outcomes Research; Edinburgh, Scotland: November 12, 1999.

Crawford B, Evans C, Benford M, Karavali M. The use of international, disease specific, cross-sectional databases for pharmacoeconomic research. Edinburgh, Scotland: November (11-12), 1999.

Marquis P, Evans C. Practical strategies in outcomes research to support new products. IRR; London, England: October 13, 1999.

Evans C, Crawford B. Data collection methods in economic evaluations: implications for study validity, evidence rankings and league tables. HESG; Aberdeen, Scotland: July (14-16), 1999.

Keresteci MA, Ungar W, Ryan N, Mendelson L, Tarlo S, Nadal JC, Rosano ME, Evans C. Development of a nasal comfort index for nasal sprays in adults with seasonal allergic rhinitis. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual International Meeting; Crystal City, VA, USA: May (23-26), 1999.

Crawford B, Evans C. Data collection methods for resource utilization: choosing the right approach. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual International Meeting; Crystal City, VA, USA: May (23-26), 1999.

Wilson DA, Gammans RE, Evans CJ. Cost of ischemic stroke treatment by functional status: a model comparing citicoline to standard care. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual International Meeting; Crystal City, VA, USA: May (23-26), 1999.

Evans C, Dukes E, Bailey L, Crawford B. Pharmacoeconomic information in formulary decision making in the United States. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual International Meeting; Crystal City, VA, USA: May (23-26), 1999.

Crawford B, Dukes E, Bailey L, Evans C. The role of quality of life information in managed care decision making. International Society for Pharmacoeconomics and Outcomes Research Fourth Annual International Meeting; Crystal City, VA, USA: May (23-26), 1999.

Henke CJ, Miller DP, Armitage GC, Eber RM, Genco RJ, Killoy WJ, Mellonig JT, Page RC, Polson AM, Ryder MI, Somerman MJ, Van Dyke TE, Wolff LF, Yukna RA, Evans CJ, Finkelman RD. Economic evaluation of a chlorhexidine chip for treating adult periodontitis. International and American Association for Dental Research; Vancouver, Canada: March (9-13), 1999.

Wunderlich DA. Threats to Validity. University of Nebraska. 1999.

Wunderlich DA. The Process of Path Analysis. University of Nebraska. 1999.

Wunderlich DA, Flowers JH. Multimedia Presentation of Information Fails to Enhance Memory. American Psychological Society; Denver, CO: 1999.

Wunderlich DA. The Efficacy of Using Sound to Enhance Graphically Presented Numerical Information. Great Plains Students’ Psychology Convention; Wichita, KS: 1999.

Crawford B, Evans C. Self reported resource utilization data in pharmacoeconomic trials: their use and impact on study validity. International Society for Pharmacoeconomics and Outcomes Research Inaugural European Conference; Cologne, Germany: December (10-12), 1998.

Crawford B, Evans C. Designing an international piggyback study: providing the foundation. International Society for Pharmacoeconomics and Outcomes Research Inaugural European Conference; Cologne, Germany: December (10-12), 1998.

Crawford B, Evans C, Abetz L. The use of proxies to collect health care resources and quality of life data. International Society for Pharmacoeconomics and Outcomes Research Inaugural European Conference; Cologne, Germany: December (10-12), 1998.

Evans C, Crawford B. Direct medical costs: perspectives and techniques. DIA Economic Assessment in Clinical Trials; New Orleans, LA, USA: November (9-10), 1998.

Crawford B, Evans C. The use of patient self-reports to collect health care resource utilization. Third Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research; Philadelphia, PA, USA: May (27-29), 1998.

Lorber M, Evans C, Fastenau J, DiCesare J, Hall M on behalf of the US Simulect Group. An economic evaluation of Basiliximab (Simulect) for the prevention of acute cellular rejection in renal allograft recipients. American Society of Transplant Physicians; Chicago, IL, USA: May (9-13), 1998.

Evans C, Crawford B, Wilson D. Threats to validity in prospective economic evaluations. HESG: January, 1998.

Wunderlich DA. Specificity and Pattern Theories of Perception. Nebraska Wesleyan University; Lincoln, NE: 1998.

Wilson D, Evans C, Fitzsimon C. International economic comparison of stroke treatment of citicoline to standard care. North American Stroke Meeting; Montreal, Canada: October (16-18), 1997.

Evans CJ, Cascade EF. Utilizing pharmacoeconomic modeling to support oncology research, marketing and disease management strategies. Managed Oncology Care: April, 1997.

Evans C. The use of delphi, modified delphi and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. HESG: January, 1997.

Evans C. The development of health care delivery efficiency indexes: a preliminary investigation. Strategic Issues in Health Care Management: March, 1994.

Evans C. The impact of World Bank and IMF structural adjustment loans on health conditions, health care delivery and health status in sub-saharan Africa. Strategic Issues in Health Care Management: March, 1994.

Evans C, Phillips J. Alternative methods of health care delivery in developing countries: three case studies. HESG: January, 1993.

Book Chapters

Kopp ZS, Evans CJ, Brubaker LP. PRO questionnaires to screen and measure satisfaction, expectations and goal achievement. In Cardozo and D Staskin (eds.) Textbook of Female Urology and Urogynecology (Third Edition). London, Informa Healthcare, 2010.

Evans C, Horowicz-Mehler N. Pharmacoeconomics in pain research. In Harriet Wittink and Daniel Carr (eds.) Pain Management: Evidence, Outcomes and Quality of Life. New York, Elsevier, 2008.

Evans C. The pharmaceutical industry and productivity research. In R. Kessler, P. Stang (eds.). Health and Work Productivity: Making the Business Case for Quality Health Care. Chicago: University of Chicago Press, 2006.

Evans C, Kennedy L, Crawford B, Malek M. From guidelines to good practice: improving the quality of economic evaluations. In M Tavakoli, H.T.O Davies and M. Malek (eds.) Health Policy and Economics: Strategic Issues in Health Care Management. Ashgate Publishing Ltd, 2001.

Evans C, Kennedy L, Crawford B. The use of databases in health economics and outcomes research: an international perspective. In M Tavakoli, H.T.O Davies and M. Malek (eds.) Health Policy and Economics: Strategic Issues in Health Care Management. Ashgate Publishing Ltd, 2001.

Malek M, Rasquinha J, Vacani P, Evans C. Health care delivery efficiency indexes – the search for the holy grail. In M. Malek et al. (eds.) Strategic Issues in Health Care Management. New York: John Wiley and Sons, 2001.

j

RESEARCH

Development of Pediatric Illustrations for Concept Elicitation Interviews

In 2018, researchers at Endpoint Outcomes embarked on an exercise to develop illustrations to assist pediatric research participants in communicating their disease experience to our interviewers.  A list of concepts commonly found in pediatric diseases was developed based on a review of generic pediatric health-related quality of life measures.  Draft illustrations were initially developed by a professional illustrator to reflect the core concepts.  The draft illustrations were then reviewed by staff at Endpoint Outcomes to ensure they reflect the relevant concepts and illustrations were subsequently altered if necessary. The illustrations have been developed to be gender and ethnicity/race neutral and to focus on disease deficits.  Currently, the illustrations are being pilot tested in two pediatric studies in rare diseases. A formal evaluation of the content validity of the measures is planned for later in the year. For additional information on this work please contact Shayna Egan: Shayna.egan@endpointoutcomes.com

Qualitative Research to Support the Selection of Appropriate Rating Scales and Response Options

During Q4 2013 through Q2 2014 Endpoint Outcomes embarked on a large study to examine the selection of rating scales and response options for patient reported outcome (PRO) measures from the patient’s perspective.  This research, which was a mix of closed-ended exercises supplemented with qualitative interviews, sought to broaden our understanding of the best scales and response options to use in the development or PRO measures.  This work was conducted in 400 patients representing four chronic conditions.  This research examined a variety of topics related to measurement, including but not limited to:

  • Patient preference for visual analogue scale (VAS) – horizontal (VAS-H), VAS-vertical (VAS-V), numeric rating scale (NRS), NRS-box plot and verbal descriptor scale (VDS)
  • Level of agreement between VAS-V, NRS, NRS-box plot and VDS
  • Whether VDSs have interval properties or are purely categorical
  • The appropriate number of categories on a VDS (none, mild, moderate and severe vs. none, very mild, moderate, severe, and very severe)
  • Appropriate descriptors for VDSs
  • Preference for 24 hour recall instructions
  • Patient memory retrieval process for symptoms assessments
    • For example, when patients are asked to recall the severity of a symptom do they recall the sensation of the symptom (e.g., pain intensity) or do they recall the impact of the symptom on functioning (e.g., because of pain they could not do physical activities)

We have presented select results to date, including:

  • Proximal versus distal impacts of disease: drivers of bothersomeness ratings in patient-reported outcomes studies.
  • What is being measured in patient-reported outcome measures? Symptom questions may often reveal impact answers.
  • Are patients’ responses to five point verbal descriptor scales and visual analogue scales replicate measures? An experimental manipulation.
  • Pain assessment: a myriad of techniques to measure pain severity – does it matter which one is used?
  • Where is your abdomen? Patient-reported abdomen locations and implications for patient-reported outcome assessments.